Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.
Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (ESG) issues. Amgen also was named to the DJSI North America Index for the ninth straight year.
Biopharmaceutical stocks are slated to end the year on a sour note. This industrywide sell-off has also picked up momentum during the waning days of Nov., with an eye-popping 358 biopharma stocks falling by more than 10% during just the past three weeks. Savvy investors, though, know that steep drops in the market typically represent compelling buying opportunities.